placeholder
Importance
45
Trust
71
Urgency
30
Daewoong adds long-acting GLP-1 shot to oral, microneedle obesity push - koreabiomed.com
Daewoong, a South Korean company, is developing multiple versions of a GLP-1 drug (a weight-loss medicine) including a long-acting injection, a pill, and a microneedle patch. The company is expanding its pipeline to compete in the growing obesity treatment market.
Analysis
Daewoong joins the crowded GLP-1 race with three drug formats. It will take years before any of these reach patients or pose a real threat to Novo and Lilly.
- Daewoong is building a long-acting GLP-1 injection for obesity
- Pipeline also includes an oral pill and a microneedle patch version
- South Korean drugmaker pushing into the global obesity drug market
Semaglutide News1mo
Read